This opportunity is not yet open for proposals. Use this time to prepare — engaging early (capability statement, contacting the agency) can position you for the upcoming solicitation.
The National Institutes of Health is procuring modifications to the A11 HERV-E TCR and T cell product aimed at enhancing therapeutic efficacy for patients with clear cell renal cell carcinoma (ccRCC). The key focus is on improving treatment outcomes for this specific patient population.
Get your fit score, win probability, and required capabilities.
No description available
Get matched to contracts like this daily
Free AI-powered contract matching for your business.